Goldman Sachs downgraded Luye Pharma to Sell from Neutral with a price target of HK$3.73, up from HK$3.68. The firm sees modest product sales growth in the coming years and views earnings improvement from potential debt pay-down as reflected in the share price, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>